The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With HER2 Over Expression
Clinical trial NCT07662473 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07662473
- Sponsor
- Hunan Province Tumor Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-29
- Primary completion
- 2027-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.